Evaluation of Fondaparinux in Patients With a Heart Rhythm Disturbance Who Undergo Restoration of Normal Heart Rhythm
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether Fondaparinux is effective and safe to prevent
thromboembolic events (like for example strokes) and bleeding events in patients who undergo
a normalisation of their heart rhythm disturbance. Fondaparinux will be compared with Heparin
and tablets containing Vitamin-K-Antagonists (Phenprocoumon, Fluindione, or Warfarin).
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Calcium heparin Fondaparinux Heparin PENTA Vitamin K Vitamins